AI generated
Aug 11, 2026, 13:34
Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
Brett Hoover, Senior Director of Global Project Management, Medical Imaging and Specialty Solutions at Clario, shared a post on LinkedIn:
“New CCTA Study Suggests that Current Plaque is the Key Biomarker for Assessing major adverse cardiovascular events (MACE) risk.
Emerging research demonstrates that those with total plaque volume more than 750 mm3 have an 18.6 percent risk of MACE at four years in comparison to a 1.4 percent MACE risk for those with no plaque.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian